Radiotherapy-Induced Tumor Lysis Syndrome

Pathophysiology and Clinical Presentation

Radiation therapy can trigger massive tumor cell lysis, leading to the release of intracellular contents into the bloodstream, including potassium, uric acid, and phosphate, in patients with solid tumors, particularly breast cancer, as noted by the Journal of Clinical Oncology 1, 2
The clinical presentation of tumor lysis syndrome typically manifests within 12-72 hours after initiation of cytoreductive therapy, which matches the timeline of patients undergoing radiotherapy, according to the Journal of Clinical Oncology 2
Hyperuricemia occurs due to the catabolism of purine nucleic acids from lysed tumor cells to uric acid, which precipitates in renal tubules, as described in the Journal of Clinical Oncology 1, 2
Hyperkalemia results from the rapid release of intracellular potassium from lysed cells, exacerbated by concurrent renal failure, as reported in the Journal of Clinical Oncology 1, 2
Acute kidney injury is caused by uric acid crystal deposition in renal tubules, leading to obstruction and renal insufficiency, reflected in elevated creatinine levels, according to the Journal of Clinical Oncology 1, 2

Risk factors for tumor lysis syndrome in solid tumors include bulky disease, high sensitivity to treatment, pre-existing renal impairment, and elevated LDH levels, as identified in Haematologica 3, 4
The American Society of Clinical Oncology recommends immediate intervention for life-threatening hyperkalemia and severe acute kidney injury, including cardiac monitoring, hypertonic glucose with insulin, and calcium gluconate, although the specific guideline is not mentioned in the article 1, 2
Dialysis should be initiated immediately for patients with persistent severe hyperkalemia, severe renal impairment, and likely severe metabolic acidosis, as suggested in Haematologica 5
Frequent dialysis is recommended considering the continuous release of metabolites from ongoing tumor cell lysis, according to Haematologica 5
Rasburicase is the preferred agent for established tumor lysis syndrome with hyperuricemia, as it rapidly converts uric acid to the more soluble allantoin, as described in Haematologica 4
Aggressive intravenous hydration is necessary to improve renal perfusion and promote urinary excretion of uric acid and phosphate, as recommended in Haematologica 3, 4

The most dangerous pitfall is failing to recognize tumor lysis syndrome in solid tumor patients receiving radiotherapy, leading to delayed diagnosis and treatment, as warned in Haematologica 3